Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mats Eriksson

Showing results (221-230 of 241) with videos related to

Pageof 25
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|October 2, 2010
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humansLena Persson, Guoqing Cao, Lars Ståhle, et al.
Circulation|September 29, 2004
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liverPaolo Parini, Matthew Davis, Aaron T Lada, et al.
Clinical Therapeutics|May 4, 2010
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trialRoeland Huijgen, Evertine J Abbink, Eric Bruckert, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
BMJ Open|March 10, 2022
What is the definition of acute episodic and chronic pain in critically ill neonates and infants? A global, four-stage consensus and validation studyEmre Ilhan, Verity Pacey, Laura Brown, et al.
Atherosclerosis Plus|January 16, 2023
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI studyKausik K Ray, Inaam Haq, Aikaterini Bilitou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2016
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell ProtectionJonas W Brinck, Aurélien Thomas, Estelle Lauer, et al.
European Journal of Preventive Cardiology|June 11, 2024
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI studyKausik K Ray, Carlos Aguiar, Marcello Arca, et al.
The Lancet Regional Health. Europe|April 24, 2023
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI studyKausik K Ray, Inaam Haq, Aikaterini Bilitou, et al.
American Journal of Preventive Cardiology|June 15, 2026
Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI studyKausik K Ray, Carlos Aguiar, Marcello Arca, et al.
Pageof 25

Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Arteriosclerosis, Thrombosis, and Vascular Biology|October 2, 2010
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humansLena Persson, Guoqing Cao, Lars Ståhle, et al.
Circulation|September 29, 2004
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liverPaolo Parini, Matthew Davis, Aaron T Lada, et al.
Clinical Therapeutics|May 4, 2010
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trialRoeland Huijgen, Evertine J Abbink, Eric Bruckert, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
BMJ Open|March 10, 2022
What is the definition of acute episodic and chronic pain in critically ill neonates and infants? A global, four-stage consensus and validation studyEmre Ilhan, Verity Pacey, Laura Brown, et al.
Atherosclerosis Plus|January 16, 2023
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI studyKausik K Ray, Inaam Haq, Aikaterini Bilitou, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2016
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell ProtectionJonas W Brinck, Aurélien Thomas, Estelle Lauer, et al.
European Journal of Preventive Cardiology|June 11, 2024
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI studyKausik K Ray, Carlos Aguiar, Marcello Arca, et al.
The Lancet Regional Health. Europe|April 24, 2023
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI studyKausik K Ray, Inaam Haq, Aikaterini Bilitou, et al.
American Journal of Preventive Cardiology|June 15, 2026
Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI studyKausik K Ray, Carlos Aguiar, Marcello Arca, et al.
Pageof 25